FGFR-targeted therapeutics for the treatment of breast cancer

References

• Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat Rev Clin Oncol. 2010 Mar;7(3):139–147.
   PubMed Web of Science ®Google Scholar
• Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006 Dec;10(6):529–541.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010 Jun 25;141(7):1117–1134.
   PubMed Web of Science ®Google Scholar
• Gu G, Dustin D, Fuqua S. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016 Dec;31:97–103.
   PubMed Web of Science ®Google Scholar
• Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013 Mar;14(3):166–180.
   PubMed Web of Science ®Google Scholar
• Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010 Feb;10(2):116–129.
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016 Jan;22(1):259–267.
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009 Mar;8(3):235–253.
   PubMed Web of Science ®Google Scholar
• Trueb B. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell Mol Life Sci. 2011 Mar;68(6):951–964.
   PubMed Web of Science ®Google Scholar
• Chen Y, Mcgee J, Chen XM, et al. Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS One. 2014 May;9(5):e98293.
   PubMed Web of Science ®Google Scholar
• Wesche J, Haglund K, Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011 Jul;437(2):199–213.
   PubMed Web of Science ®Google Scholar
• Ornitz DM, The fibroblast growth factor signaling pathway. Wires Dev Biol. 2015 May-Jun;4(3):215–266.
   Web of Science ®Google Scholar
• Coleman SJ, Bruce C, Chioni AM, et al. The ins and outs of fibroblast growth factor receptor signalling. Clin Sci. 2014 Aug;127(3–4):217–231.
   PubMed Web of Science ®Google Scholar
• Bryant DM, Stow JL. Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic. 2005 Oct;6(10):947–954.
   PubMed Web of Science ®Google Scholar
• Chioni A-M, Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol. 2012 Jun;197(6):801–817.
   PubMed Web of Science ®Google Scholar
• Cerliani JP, Guillardoy T, Giulianelli S, et al. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res. 2011 Sep;71(17):3720–3731.
   PubMed Web of Science ®Google Scholar
• Johnston CL, Cox HC, Gomm JJ, et al. Fibroblast Growth Factor Receptors (FGFRs) localize in different cellular compartments. The Journal of Biological Chemistry. 1995 Dec;270(51):30643–30650.
   PubMed Web of Science ®Google Scholar
• Giacomini A, Chiodelli P, Matarazzo S, et al. Blocking the FGF/FGFR system as a “two-compartment” antiangiogenic/antitumor approach in cancer therapy. Pharmacol Res. 2016;107:172–185.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Carotenuto P, et al. Prognostic applications of gene expression signatures in breast cancer. Oncology-Basel. 2009;77:2–8.
   PubMed Web of Science ®Google Scholar
• Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997 Oct;57(19):4360–4367.
   PubMed Web of Science ®Google Scholar
• Ray ME, Yang ZQ, Albertson D, et al. Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines. Cancer Res. 2004 Jan;64(1):40–47.
   PubMed Web of Science ®Google Scholar
• Garcia MJ, Pole JC, Chin SF, et al. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene. 2005 Aug;24(33):5235–5245.
   PubMed Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010 Mar;70(5):2085–2094.
   PubMed Web of Science ®Google Scholar
• Fumagalli D, Wilson TR, Salgado R, et al. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Annals of Oncology. 2016 Oct;27(10):1860–1866.
   PubMed Web of Science ®Google Scholar
• Cuny M, Kramar A, Courjal F, et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res. 2000 Feb;60(4):1077–1083.
   PubMed Web of Science ®Google Scholar
• Jones DT, Hutter B, Jager N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug;45(8):927–932.
   PubMed Web of Science ®Google Scholar
• Rand V, Huang J, Stockwell T, et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc Natl Acad Sci USA. 2005 Oct 4;102(40):14344–14349.
   PubMed Web of Science ®Google Scholar
• Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012 Sep 7;337(6099):1231–1235.
   PubMed Web of Science ®Google Scholar
• Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010 Apr;29(14):2013–2023.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Arao T, Hamaguchi T, et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 2012 Feb 14;106(4):727–732.
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA. 2008 Jun 24;2008:8713–8717.
   Web of Science ®Google Scholar
• Liao RG, Jung J, Tchaicha J, et al. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 2013 Aug 15;73(16):5195–5205.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.
   PubMed Web of Science ®Google Scholar
• Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013 Jun;3(6):636–647.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van Tilborg AA, Lurkin I, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002 Dec;10(12):819–824.
   PubMed Web of Science ®Google Scholar
• Rosty C, Aubriot MH, Cappellen D, et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer. 2005;4(1):15.
   PubMed Web of Science ®Google Scholar
• Wang R, Wang L, Li Y, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res. 2014 Aug;20(15):4107–4114.
   PubMed Web of Science ®Google Scholar
• Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015 Jun;21(12):2684–2694.
   PubMed Web of Science ®Google Scholar
• Bane AL, Pinnaduwage D, Colby S, et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat. 2009 Sep;117(1):183–191.
   PubMed Web of Science ®Google Scholar
• Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007 Jun;447(7148):1087–1093.
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007 Jul;39(7):870–874.
   PubMed Web of Science ®Google Scholar
• Antoniou AC, Spurdle AB, Sinilnikova OM, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 2008 Apr;82(4):937–948.
   PubMed Web of Science ®Google Scholar
• Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002 Feb;62(3):840–847.
   PubMed Web of Science ®Google Scholar
• Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013 Feb;22(4):795–803.
   PubMed Web of Science ®Google Scholar
• Dienstmann R, Rodon J, Prat A, et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Annals of Oncology. 2014 Mar;25(3):552–563.
   PubMed Web of Science ®Google Scholar
• Lee SH, Lopes de Menezes D, Vora J, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res. 2005 May;11(10):3633–3641.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774–4782.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401–412.
   PubMed Web of Science ®Google Scholar
• Matsui J, Yamamoto Y, Funahashi Y, et al. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008 Feb 1;122(3):664–671.
   PubMed Web of Science ®Google Scholar
• Bello E, Colella G, Scarlato V, et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb;71(4):1396–1405.
   PubMed Web of Science ®Google Scholar
• Hall TG, Yu Y, Eathiraj S, et al. Preclinical activity of ARQ 087, a novel inhibitor targeting FGFR dysregulation. Plos One. 2016;11(9):e0162594.
   PubMed Web of Science ®Google Scholar
• Sarker D, Molife R, Evans TR, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2008 Apr;14(7):2075–2081.
   PubMed Web of Science ®Google Scholar
• Andrè F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013 Jul;19(13):3693–3702.
   PubMed Web of Science ®Google Scholar
• Soria JC, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014 Nov;25(11):2244–2251.
   PubMed Web of Science ®Google Scholar
• Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr;72(8):2045–2056.
   PubMed Web of Science ®Google Scholar
• Andrè F, Ranson M, Dean E, et al. Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research 2013 Cancer Res. 2013;73(8 Suppl): Abstract nr LB-145 2013.
   Web of Science ®Google Scholar
• Smyth EC, Turner N, Peckitt C, et al. Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. J Clin Oncol. 2015;33(suppl; abstr 2508).
   Google Scholar
• Angibaud P, Mevellec L, Saxty G, et al. Discovery of JNJ-42756493, a potent fibroblast growth factor receptor (FGFR) inhibitor using a fragment based approach. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 2014 Cancer Res. 2014;74(19 Suppl): Abstract nr 4748.
   Web of Science ®Google Scholar
• Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012 Dec;2(12):1118–1133.
   PubMed Web of Science ®Google Scholar
• Ochiiwa H, Fujita H, Itoh K, et al. TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Mol Cancer Ther. 2013;12(11 Suppl):A270.
   Web of Science ®Google Scholar
• Zhao G, Li WY, Chen D, et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol Cancer Ther. 2011 Nov;10(11):2200–2210.
   PubMed Web of Science ®Google Scholar
• Harding TC, Long L, Palencia S, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med. 2013 Mar;5(178):178ra39.
   PubMed Web of Science ®Google Scholar
• Castelli R, Giacomini A, Anselmi M, et al. Synthesis, structural elucidation, and biological evaluation of NSC12, an orally available Fibroblast Growth Factor (FGF) Ligand trap for the treatment of FGF-dependent lung tumors. J Med Chem. 2016 May;59(10):4651–4663.
   PubMed Web of Science ®Google Scholar
• Bai A, Meetze K, Vo NY, et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010 Oct;70(19):7630–7639.
   PubMed Web of Science ®Google Scholar
• Yin Y, Djakovic S, Marsters S, et al. Redesigning a monospecific anti-FGFR3 antibody to add selectivity for FGFR2 and expand antitumor activity. Mol Cancer Ther. 2015 Oct;14(10):2270–2278.
   PubMed Web of Science ®Google Scholar
• ODonnell P, Goldman J, Gordon M, et al. A phase I dose-escalation study of MFGR1877S, a human monoclonal anti-fibroblast growth factor receptor 3 (FGFR3) antibody, in patients (pts) with advanced solid tumors. Eur J Cancer. 2012;48(Suppl. 6):191–192.
   Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015 Oct;33(30):3401–3408.
   PubMed Web of Science ®Google Scholar
• Bahleda R, Dienstmann R, Adamo B, et al. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32(suppl; abstr 2501):5s.
   PubMedGoogle Scholar
• Sequist L, Cassier P, Varga A, et al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research 2014 Cancer Res. 2014;74(19 Suppl): Abstract nr CT326.
   Google Scholar
• Sootome H, Fujioka Y, Miura A, et al. TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors. Mol Cancer Ther. 2013;12(11 Suppl):A271.
   Web of Science ®Google Scholar
• Tan L, Wang J, Tanizaki J, et al. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci USA. 2014 Nov;111(45):E4869–E4877.
   PubMed Web of Science ®Google Scholar
• Zhou WJ, Hur W, McDermott U, et al. A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol. 2010 Mar;17(3):285–295.
   PubMedGoogle Scholar
• Tolcher AW, Papadopoulos KP, Patnaik A, et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol. 2016 Mar;27(3):526–532.
   PubMed Web of Science ®Google Scholar
• Andrè F, Cortes J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat. 2015 Feb;150(1):1–8.
   PubMed Web of Science ®Google Scholar
• Gelsi-Boyer V, Orsetti B, Cervera N, et al. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res. 2005 Dec;3(12):655–667.
   PubMed Web of Science ®Google Scholar
• Yang ZQ, Streicher KL, Ray ME, et al. Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res. 2006 Dec 15;66(24):11632–11643.
   PubMed Web of Science ®Google Scholar
• Sharpe R, Pearson A, Herrera-Abreu MT, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clinical Cancer Res. 2011 Aug;17(16):5275–5286.
   PubMed Web of Science ®Google Scholar
• Normanno N, Rachiglio AM, Roma C, et al. Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem. 2013 Mar;114(3):514–524.
   PubMed Web of Science ®Google Scholar
• Parish A, Schwaederle M, Daniels G, et al. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015;14(13):2121–2128.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Favero F, de Bruin EC, et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med. 2015 Apr;7(283) 283ra54.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Irrthum A, Swanton C, et al. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015 Jul;12(7):381–394.
   PubMed Web of Science ®Google Scholar
• Issa A, Gill JW, Heideman MR, et al. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res. 2013;15(1):R8.
   PubMed Web of Science ®Google Scholar
• Lieu C, Heymach J, Overman M, et al. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011 Oct 1;17(19):6130–6139.
   PubMed Web of Science ®Google Scholar